{"id":"NCT02030600","sponsor":"Novo Nordisk A/S","briefTitle":"A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes","officialTitle":"A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01-06","primaryCompletion":"2015-12-04","completion":"2015-12-04","firstPosted":"2014-01-08","resultsPosted":"2017-01-30","lastUpdate":"2019-05-10"},"enrollment":721,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"insulin degludec","otherNames":[]},{"type":"DRUG","name":"insulin glargine","otherNames":[]}],"arms":[{"label":"IDeg OD ± OADs followed by IGlar OD ± OADs","type":"EXPERIMENTAL"},{"label":"IGlar OD ± OADs followed by IDeg OD ± OADs","type":"ACTIVE_COMPARATOR"}],"summary":"This trial is conducted in the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar) with or without OADs (oral anti-diabetic drugs) excluding SUs (sulfonylureas)/glinides in subjects with type 2 diabetes.","primaryOutcome":{"measure":"Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period","timeFrame":"After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64)","effectByArm":[{"arm":"Insulin Degludec (IDeg)","deltaMin":353,"sd":null},{"arm":"Insulin Glargine (IGlar)","deltaMin":496,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":166,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["30705500","28672317","30097995","30362250","30891886"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":64,"n":671},"commonTop":["Nasopharyngitis","Upper respiratory tract infection"]}}